Health & TechA malaria vaccine blocked infection in 87% of volunteers in an early trial
In an NIH-sponsored phase 1 challenge trial led by UW Medicine, 13 of 15 people given PfSPZ-LARC2 stayed infection-free against a different malaria strain, versus none of 7 on placebo. Larger trials are still ahead.
Verified · UW Medicine Newsroom






















